Ultragenyx Pharmaceutical (RARE) – This is a biopharmaceutical company that develops novel therapies for rare and ultra-rare genetic diseases. The stock has received 12 ratings in the past 72 hours. The analyst consensus on the stock is Strong Buy, with an average price target of $80.64, suggesting a potential upside of 168.26%.